SEC Form 4 · accession 0001493152-18-010074

Adhera Therapeutics, Inc. · ATRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jul 12, 2018

Accepted (ET)

Jul 16, 2018 · 8:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000737207

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series F Convertible Preferred Stock^F2,F1	$0.50	Jul 12, 2018	P	40	A	Jul 12, 2018	—	common stock	400,000	40	I
Warrants to Purchase Common Stock^F2,F3	$0.55	Jul 12, 2018	P	300,000	A	Jul 12, 2018	—	common stock	300,000	300,000	I

F1Each outstanding share of Series F Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the issuer's private placement of shares of its Series F Preferred Stock and warrants to purchase shares of its common stock (the "Offering") that the closing price of the Issuer's common stock on each of the trading days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series F Preferred Stock elect to convert all of the outstanding shares of Series F Preferred Stock.
F2The reporting person is the majority member and manager of the general partner of the entity that holds the applicable securities. In such position, the reporting person has the power to control the voting and disposition of the applicable securities.
F3The warrants expire on the five year anniversary of the closing of the Offering.